Patient stem cells offer a promising way to test potential therapies for rare diseases Raloxifene, a medication used to prevent bone loss in postmenopausal women, was able to reduce fibrosis, or scarring, in cell and mouse models of systemic sclerosis (SSc).
The research team noted that the patient stem cell-based model they used offers a promising way to evaluate therapeutic candidates for rare diseases like SSc.
The study, “Anti-fibrotic effect of a selective estrogen receptor modulator in systemic sclerosis,” was published in the journal Stem Cell Research & Therapy.